Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - BRAINSTORM CELL THERAPEUTICS INC. | tv486802_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - BRAINSTORM CELL THERAPEUTICS INC. | tv486802_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - BRAINSTORM CELL THERAPEUTICS INC. | tv486802_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - BRAINSTORM CELL THERAPEUTICS INC. | tv486802_ex31-1.htm |
| EX-21 - EXHIBIT 21 - BRAINSTORM CELL THERAPEUTICS INC. | tv486802_ex21.htm |
| EX-10.50 - EXHIBIT 10.50 - BRAINSTORM CELL THERAPEUTICS INC. | tv486802_ex10-50.htm |
| EX-10.45 - EXHIBIT 10.45 - BRAINSTORM CELL THERAPEUTICS INC. | tv486802_ex10-45.htm |
| 10-K - FORM 10-K - BRAINSTORM CELL THERAPEUTICS INC. | tv486802_10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference to Registration Statement Nos. 333-131880, 333-168763, 333-175460, 333-182546 and 333-198391 on Form S-8 and Nos. 333-201704, 333-201705 and 333-204718 on Form S-3 of our report dated March 8, 2018, relating to the financial statements of BRAINSTORM CELL THERAPEUTICS INC. (which report expresses an unqualified opinion and includes an explanatory paragraph regarding the Company’s ability to continue as a going concern) appearing in this Annual Report on Form 10-K of BRAINSTORM CELL THERAPEUTICS INC. for the year ended December 31, 2017.
| /s/ Brightman Almagor Zohar & Co. | |
| Brightman Almagor Zohar & Co. | |
| Member of Deloitte Touche Tohmatsu Limited | |
| Tel Aviv, Israel |
March 8, 2018